Navigation Links
INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
Date:10/25/2011

PISCATAWAY, N.J., Oct. 25, 2011 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for olanzapine injection (the generic equivalent of Zyprexa® injection).

As the developer of this generic injectable drug, INNOPHARMA entered into an agreement with Sandoz Inc., pursuant to which Sandoz will sell, market and distribute the product in the United States.  

About INNOPHARMA:

INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.    

Zyprexa® is a registered trademark of Eli Lilly and Company


'/>"/>
SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. INNOPHARMA Receives FDA Approval of Generic Levetiracetam Injection
2. INNOPHARMA Receives First FDA Approval
3. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
4. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
5. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
6. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
7. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
8. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
9. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
10. NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
11. HipSextant™ Navigation System Receives Its First Commercial Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):